CEL-SCI (NYSE:CVM) Upgraded at StockNews.com

CEL-SCI (NYSE:CVM) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

CEL-SCI Stock Performance

CVM opened at $0.63 on Tuesday. CEL-SCI has a 12-month low of $0.63 and a 12-month high of $3.23. The stock has a market cap of $40.21 million, a price-to-earnings ratio of -1.09 and a beta of 0.69. The business has a 50 day moving average of $0.98 and a 200-day moving average of $1.16. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00.

CEL-SCI (NYSE:CVM) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, equities research analysts expect that CEL-SCI will post -0.52 earnings per share for the current year.

Hedge Funds Weigh In On CEL-SCI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC bought a new position in shares of CEL-SCI in the 1st quarter valued at $27,000. Calton & Associates Inc. bought a new stake in CEL-SCI during the 3rd quarter worth $50,000. Black Diamond Financial LLC grew its position in CEL-SCI by 35.8% during the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the last quarter. Cutter & CO Brokerage Inc. grew its position in CEL-SCI by 29.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after acquiring an additional 24,634 shares during the last quarter. Finally, Thoroughbred Financial Services LLC lifted its holdings in CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares during the period. 12.08% of the stock is owned by institutional investors and hedge funds.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.